Enables several functions, including ATP binding activity; ATP hydrolysis activity; and amyloid-beta binding activity. Involved in several processes, including amyloid-beta clearance by cellular catabolic process; amyloid-beta metabolic process; and negative regulation of proteolysis. Located in cell surface; extracellular space; and peroxisomal matrix. Part of cytosolic proteasome complex. Used to study Alzheimer's disease and type 2 diabetes mellitus. Biomarker of Alzheimer's disease and metabolic dysfunction-associated steatotic liver disease. Human ortholog(s) of this gene implicated in type 2 diabetes mellitus. Orthologous to human IDE (insulin degrading enzyme); PARTICIPATES IN Alzheimer's disease pathway; INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 2,6-dinitrotoluene; 2-nitrofluorene.
[Clofibrate co-treated with Acetaminophen] affects the expression of IDE mRNA and PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of IDE mRNA]
[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin affects the expression of IDE protein] and Naproxen inhibits the reaction [Capsaicin affects the expression of IDE protein]
[Clofibrate co-treated with Acetaminophen] affects the expression of IDE mRNA and PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of IDE mRNA]
[LDN 193189 co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with FGF2 protein] results in decreased expression of IDE protein
[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin affects the expression of IDE protein] and Sumatriptan inhibits the reaction [Capsaicin affects the expression of IDE protein]
Insulin deprivation decreases insulin degrading enzyme levels in primary cultured cortical neurons and in the cerebral cortex of rats with streptozotocin-induced diabetes.
Effect of growth differentiation factor-15 secreted by human umbilical cord blood-derived mesenchymal stem cells on amyloid beta levels in in vitro and invivo models of Alzheimer's disease.
Multifunctional Compound AD-35 Improves Cognitive Impairment and Attenuates the Production of TNF-a and IL-1ß in an Aß25-35-induced Rat Model of Alzheimer's Disease.
The catalytic domain of insulin-degrading enzyme forms a denaturant-resistant complex with amyloid beta peptide: implications for Alzheimer disease pathogenesis.
Neuroprotective mechanism of Kai Xin San: upregulation of hippocampal insulin-degrading enzyme protein expression and acceleration of amyloid-beta degradation.